Eckert & Ziegler SE reaffirmed its full-year 2026 guidance for revenue of 320 million and adjusted EBIT of 80 million despite flat first-half group revenue of approximately 150 million. Radiopharmaceutical sales grew 3% year-over-year, or double digits when adjusted for a prior-year license deal, while adjusted EBIT was slightly lower due to the missing license deal and a less favorable isotope product mix. Net income rose 5%, supported by positive financial results, and the medical segment's adjusted EBIT grew 7% with a margin above 30%. The isotope segment saw adjusted EBIT decline 24% on weaker industrial and oil well logging sales, though Q2 adjusted EBIT was only 5% below the prior year, a sharp improvement from Q1's nearly 50% decline. Cash and receivables remained above 100 million with loan liabilities reduced to 10 million, and the company expects a 5 million license payment in the second half to support its full-year targets.
Eckert & Ziegler Strahlen- und Medizintechnik AGReaffirms 2026 guidance despite flat revenue and mixed segment results
Van Lanschot NV